Home
Clinical Trials
Optimized Antiplatelet Therap...

Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVas™ BRS System

Last Updated: 2021-08-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

Total Enrollment

2150 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-09-30

Study Completion Date

2028-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is designed to verify the safety and efficacy of Lepu® NeoVas™ Bioabsorbable Coronary Artery Rapamycin-eluting Stent System combined with different antiplatelet therapies in the treatment of coronary heart disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Rivaroxaban in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention

NCT02334254

Atrial Fibrillation

UNKNOWN PHASE4

Intracoronary Stenting and Antithrombotic Regimen: Lesion Platelet Adhesion as Selective Target of Endovenous Revacept

NCT03312855

Stable Coronary Artery Disease

COMPLETED PHASE2

Rivaroxaban for Slow Coronary Flow After PCI in STEMI

NCT07195812

ST Elevation Myocardial Infarction No-Reflow Phenomenon

NOT_YET_RECRUITING PHASE4

Optimized Antithrombotic Therapy of Acute Myocardial Infarction With Left Ventricular Mural Thrombus

NCT03415386

Acute Myocardial Infarction Left Ventricular Thrombus

UNKNOWN PHASE4

A Study of Low-dose Intracoronary Thrombolytic Therapy in STEMI (Heart Attack) Patients.

NCT03998319

STEMI Elevated IMR (>32)

RECRUITING PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A total of 2150 subjects are planned to be enrolled in this trial. Subjects meeting the inclusion criteria and without exclusion criteria are implanted with NeoVas™ stents and randomly assigned to the experimental group and the control group in a 1:1 ratio. Patients in both groups will receive aspirin in combination with a P2Y12 receptor antagonist in the first year after PCI (either clopidogrel or ticagrelor will be selected by investigators according to the degree of ischemia). Aspirin will be discontinued one year after surgery and clopidogrel will be continued until 5 years after surgery in the experimental group. The control group will continue to take dual antiplatelet (DAPT) drugs, including aspirin and clopidogrel, for 2 more years; then aspirin will be used alone from the 4th year to the 5th year.

Subjects will be followed up at 30 days, 6 months, 1 year, 2 years, 3 years, 4 years, and 5 years after surgery to observe whether the net adverse clinical events (NACEs) and other end points occur or not.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronary Heart Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Poststent SAPT treatment cohort

receiving the treatment with NeoVas™ Bioabsorbable Coronary Artery Rapamycin-eluting Stent System of Lepu Medical combined with SAPT strategy

Group Type EXPERIMENTAL

Single anti-platelet therapy

Intervention Type DRUG

Aspirin in combination with a P2Y12 receptor antagonist (either clopidogrel or ticagrelor will be selected by investigators according to the degree of ischemia) in the first year after PCI. Aspirin will be discontinued one year after surgery and clopidogrel will be continued until 5 years after surgery.

Poststent DAPT treatment cohort

receiving the treatment with NeoVas™ Bioabsorbable Coronary Artery Rapamycin-eluting Stent System of Lepu Medical combined with DAPT strategy

Group Type ACTIVE_COMPARATOR

Dual anti-platelet therapy

Intervention Type DRUG

Aspirin in combination with a P2Y12 receptor antagonist (either clopidogrel or ticagrelor will be selected by investigators according to the degree of ischemia) in the first year after PCI. Patients continue to take dual antiplatelet (DAPT) drugs, including aspirin and clopidogrel, for 2 more years; then aspirin will be used alone from the 4th year to the 5th year.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Single anti-platelet therapy

Intervention Type DRUG

Dual anti-platelet therapy

Aspirin in combination with a P2Y12 receptor antagonist (either clopidogrel or ticagrelor will be selected by investigators according to the degree of ischemia) in the first year after PCI. Patients continue to take dual antiplatelet (DAPT) drugs, including aspirin and clopidogrel, for 2 more years; then aspirin will be used alone from the 4th year to the 5th year.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

SAPT strategy DAPT strategy

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18 or above, male or non-pregnant female.
* Evidence of myocardial ischemia (e.g., stable angina, unstable angina, medium-low risk NSTEMI, STEMI with onset more than 1 week, old myocardial infarction or asymptomatic myocardial ischemia), and suitable for PCI surgery.
* The target lesion is in-situ coronary artery lesion, the total length of single lesion is no more than 40mm (the total length of stent is no more than 48mm), and the diameter of the target lesion is between 2.75mm and 3.75mm (visual measurement).
* The diameter stenosis of target lesion is ≥70% in visual (or ≥50% with clinical evidence of myocardial ischemia in that range), and the TIMI blood flow is greater than grade 1.
* The stent with diameter more than 3.0mm is allowed to overlap with another stent once, the overlapping methods could be edge to edge or at most 1mm overlap. The total number of stents per patient is no more than 4, with a maximum of 2 stents per vessel (the 2.75mm diameter stent is not allowed to overlap).
* Patient with indications for coronary artery bypass surgery.
* Aspirin and clopidogrel could be used continuously during the study.
* Patient who can understand the purpose of this trial, is willing to participate in the trial and to conduct clinical follow-up as required by the study protocol.

Exclusion Criteria

* Acute ST-segment elevation myocardial infarction within 1 week.
* Left main coronary artery disease, branch vessel diameter≥2.0mm, three-vessel coronary artery disease and bridge vessel disease; visible thrombus in the target vessel.
* Severe distortion, severe calcification that cannot be successfully predilated, and other lesions that are not suitable for stent delivery and deployment.
* Intra-stent restenosis.
* Severe heart failure (NYHA≥III or left ventricular ejection fraction\<35%).
* Severe renal insufficiency, eGFR\<30ml/min/1.73m2 or serum creatinine\>2.5mg/dL (221μmol/L).
* Patients with bleeding tendency, active gastrointestinal ulcer, history of cerebral hemorrhage or subarachnoid hemorrhage, history of stroke within half a year, fundus hemorrhage affecting vision, antiplatelet agents and anticoagulant treatment contraindications who cannot receive antithrombotic therapy.
* Patients requiring long-term oral anticoagulants during the study period.
* Patients who are pregnant, breastfeeding, or planning to become pregnant during the study period.
* Patients with malignancies, organ transplants, or drug addiction that can seriously affect study compliance.
* Patients with contraindications to aspirin, clopidogrel or ticagrelor.
* Known allergy to aspirin, clopidogrel, ticagrelor, heparin, contrast agent, polylactic acid polymer and rapamycin.
* Thrombosis occurred during previous clopidogrel treatment.
* Life expectancy is less than 36 months.
* Participated in clinical trials of other drugs or medical devices before enrollment and failed to meet the time limit of the primary end point.
* Patients who will have elective surgery within a year and need to discontinue aspirin, clopidogrel or ticagrelor.
* Subjects are deemed unsuitable for enrollment by investigators.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Yaling Han

Role: STUDY_CHAIR

The General Hospital of Northern Theater Command

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

The First Affiliated Hospital of Bengbu Medical College

Bengbu, Anhui, China

Site Status

The First Affiliated Hospital with Anhui Medical University

Hefei, Anhui, China

Site Status